中文

KURE

KraneShares MSCI All China Health Care Index UCITS ETF

Download KURE Presentation

Investment Strategy:

KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and the United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

  • China is one of the fastest growing major healthcare markets in the world with a ten-year compound annual growth rate of 13%, compared to just 3% in the United States and 2% in Japan1.
  • China is the second largest healthcare market globally with total healthcare expenditures reaching $1.02 trillion in 2019, an increase of roughly 87% over the last 5 years2.
  • There is still opportunity for considerable growth in China’s healthcare market with per capita health spending at just $441, compared to an average of over $5,400 for the world’s top eight healthcare markets3.
  • China’s aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China’s healthcare sector.

KURE features:

  • Exposure to Chinese companies listed in the Mainland, Hong Kong and United States that are involved in the healthcare industry. Specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.
  • Exposure to companies that benefit from China’s growing middle class and aging population.
  • Access to leading Chinese pharmaceutical companies which have been recipients of favorable policy and market conditions for research and development and the invention of new medicines and devices.

1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 31/Dec/2017, last updated on 7/Apr/2020. Retrieved 31/Dec/2020.

2.) Statista, Health expenditure in China 2000-2019”, Published by Lai Lin Thomala, Dec 17, 2020, Retrieved 31/Dec/2020.

3.) Data from the World Health Organization, last updated on 7/Apr/2020. Retrieved 31/Dec/2020.

Fund Details

Data as of 01/21/2021
TickerKURE
Listings LSE, ISE
SEDOLBMZ4LD0
ISINIE00BL6K0S82
Net Assets$2,662,803
Total Annual Fund Operating Expense 0.65%
Inception Date14/1/2021
Distribution FrequencyAccumulating

Fund Documents

Daily Performance

Data as of 01/21/2021
NAV
Net Asset Value$26.63 
Daily Change 0.61%

Performance History

Cumulative %
Data as of: 12/31/2020		 Fund NAV Index
1 Month– –
3 Month– –
6 Month– –
Since Inception–
Cumulative %
Data as of quarter end: 12/31/2020		 Fund NAV Index
Since Inception– –

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Top 10 Holdings

Data as of 01/21/2021
Full Holdings .CSV
Rank Company Name % of Net Assets Ticker Identifier Shares Held Market Value($)
1 WUXI BIOLOGICS CAYMAN INC 9.42% 2269 KYG970081173 17,000 250,890
2 JIANGSU HENGRU-A 6.53% 600276 CNE0000014W7 10,400 173,942
3 SHENZHEN MINDR-A 5.31% 300760 CNE100003G67 2,000 141,320
4 BEIGENE LTD-ADR 3.94% BGNE US07725L1026 294 104,955
5 WUXI APPTEC CO LTD-A 3.90% 603259 CNE1000031K4 4,200 103,923
6 ALIBABA HEALTH 3.63% 241 BMG0171K1018 28,000 96,625
7 AIER EYE HSPTL-A 3.51% 300015 CNE100000GR6 8,000 93,395
8 ZAI LAB LTD-ADR 3.05% ZLAB US98887Q1040 446 81,275
9 INNOVENT BIOLOGICS INC 2.91% 1801 KYG4818G1010 6,000 77,481
10 CHONGQING ZHIF-A 2.80% 300122 CNE100000V20 3,200 74,676

Holdings are subject to change.

Related Content:

Topics

©2021 Krane Funds Advisors, LLC
280 Park Avenue, 32nd Floor, New York, NY 10017

Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. The Funds are subject to political, social or economic instability within China which may cause decline in value. Fluctuations in currency of foreign countries may have an adverse effect to domestic currency values. Emerging markets involve heightened risk related to the same factors as well as increase volatility and lower trading volume.

Narrowly focused investments typically exhibit higher volatility. Internet companies are subject to rapid changes in technology, worldwide competition, rapid obsolescence of products and services, loss of patent protections, evolving industry standards and frequent new product productions. Such changes may have an adverse impact on performance.

This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is not, under any circumstances, intended for distribution to the general public. You are accessing information which constitutes a financial promotion under section 21 of the Financial Services and Markets Act 2000 ("FSMA"). In relation to the United Kingdom, this information is only directed at, and may only be distributed to, persons who are “Investment Professionals” (being persons having professional experience in matters relating to investments) within the meaning of article 19(5) of the FSMA (Financial Promotion) Order 2005 (the “Financial Promotion Order ”), persons to whom any of paragraphs (2)(a) to (d) of article 49 (high net worth companies, unincorporated associations eatc.) of the financial promotion order apply, or persons to whom distribution may otherwise lawfully be made.

Any investment, and investment activity or controlled activity, to which this information relates is available only to such persons and will be engaged in only with such persons. Persons that do not have professional experience should not rely or act upon this information unless they are persons to whom any of paragraphs (2)(a) to (d) of article 49 apply to whom distribution of this information may otherwise lawfully be made.

For additional fund documentation, please visit www.DMSGovernance.com

Privacy Policy

You are now leaving KraneShares.eu

Hyperlinks on this website are provided as a convenience and we disclaim any responsibility for information, services or products found on the websites linked hereto.

Click here to continue

Invest in KURELN Through Your Broker

You are now leaving KraneShares.com. Hyperlinks on these websites are provided as a convenience and we disclaim any responsibility for information, services or products found on the websites linked hereto.